WS02.01 Abdominal symptoms significantly decline after 24 weeks of elexacaftor/tezacaftor/ivacaftor treatment: first results obtained with the cystic fibrosis-specific CFAbd-Score in Germany and the UK

Mainz, J.G., Zagoya, C., Polte, L. et al. (12 more authors) (2022) WS02.01 Abdominal symptoms significantly decline after 24 weeks of elexacaftor/tezacaftor/ivacaftor treatment: first results obtained with the cystic fibrosis-specific CFAbd-Score in Germany and the UK. In: Journal of Cystic Fibrosis. 45th European Cystic Fibrosis Conference, 08-11 Jun 2022, Rotterdam, The Netherlands. Vol. 21 (Supplement 1). Elsevier. ISSN: 1569-1993. EISSN: 1873-5010.

Metadata

Item Type: Conference abstract
Authors/Creators:
  • Mainz, J.G.
  • Zagoya, C.
  • Polte, L.
  • Naehrlich, L.
  • Sasse, L.
  • Eickmeier, O.
  • Smaczny, C.
  • Baurcha, A.
  • Bechinger, L.
  • Duckstein, F.
  • Eschenhagen, P.
  • Kurzidim, L.
  • Caley, L. ORCID logo https://orcid.org/0000-0001-8957-1018
  • Peckham, D.
  • Schwarz, C.
Dates:
  • Published (online): 10 June 2022
  • Published: 10 June 2022
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Biological Sciences (Leeds) > Faculty of Biological Sciences Office (Leeds)
Funding Information:
Funder
Grant number
Cystic Fibrosis Trust
SRC012
Date Deposited: 16 Jun 2025 10:00
Last Modified: 05 Mar 2026 12:13
Status: Published
Publisher: Elsevier
Open Archives Initiative ID (OAI ID):

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics


CORE (COnnecting REpositories)